medigraphic.com
ISSN 1527-3172 (Digital)

2011, Número 2

<< Anterior Siguiente >>

MEDICC Review 2011; 13 (2)


Occult Hepatitis B in cuban HIV patients

Bello M, Montalvo MC, Rodríguez LÁ, Sariego S, Verdasquera D, Vincent M, Gutiérrez A, Sánchez M

Idioma: Ingles.
Referencias bibliográficas: 46
Paginas: 32-37
Archivo PDF: 170.24 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol. 2009 Mar;81(3):406–12.

  2. Burnett RJ, François G, Kew MC, Leroux-Roels G, Meheus A, Hoosen AA, et al. Hepatitis B virus and human immunodefi ciency virus co-infection in Sub-Saharan African: A call for further investigation. Liver Int. 2005 Apr;25(2):201–13.

  3. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev. 2007 Jan–Mar;9(1):25–39.

  4. Mphahlele MJ. Impact of HIV co-infection on hepatits B prevention and control: A view from sub- Saharan Africa. SAJEI. 2008;23(1):14–8.

  5. Fabris P, Biasin MR, Giordani MT, Berardo L, Menini V, Carlotto A, et al. Impact of occult HBV infection in HIV/HCV co-infected patients: HBVDNA detection in liver specimens and in serum samples. Curr HIV Res. 2008 Mar;6(2):173–9.

  6. Yokosuka O, Omata M, Hosoda K, Tada M, Ehata T, Ohto M. Detection and direct sequencing of hepatitis B virus genome by DNA amplifi cation method. Gastroenterology. 1991 Jan;100(1):175–81.

  7. Galbán E, Vega H, Gra B, Rodríguez A, Doval MA, Haedo D, et al. Papel de la Ribavirina en el tratamiento de la hepatitis crónica B. Gastroenterol Hepatol. 2000 Apr;23(4):165–9. Spanish.

  8. Gutiérrez C, León G, Liprandi F, Pujol FH. Low impact of silent hepatitis B virus infection on the incidence of post-transfusion hepatitis in Venezuela. Rev Panam Salud Publica. 2001 Dec;10(6):382–7.

  9. Torbenson M, Thomas DL. Occult hepatitis B infection. Lancet Infect Dis. 2002 Aug;2(8):479–86.

  10. Estruch L, Santín M, Lantero MI, Ochoa R, Joanes J, Alé K, et al. República de Cuba. Informe nacional sobre los progresos realizados en la aplicación del UNGASS. La Habana [Internet]. Geneva: UNAIDS; 2010 Mar [cited 2010 June 20]. 42 p. Available from: http://data.unaids.org/ pub/Report/2010/cuba_2010_country_progress_ report_es.pdf. Spanish.

  11. André FE. Overiew of a 5 year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 1990 Mar;8 Suppl:S74–8.

  12. Chen RW, Piiparinen H, Seppänen M, Koskela P, Sarna S, Lappalainen M. Real-Time PCR for Detection and Quantitation of Hepatitis B Virus DNA. J Med Virol. 2001 Oct;65(2):250–6.

  13. Rodriguez L, Collado F, Aragón U, Díaz B, Rivero J. Hepatitis B Virus exposure in Human Immunodefi ciency Virus seropositive Cuban patients. Mem Inst Oswaldo Cruz. 2000 Mar– Apr;95(2):243–5.

  14. Delgado G. Situación de la Hepatitis B en Cuba. Actas del Taller Nacional de Hepatitis; 2008 Jun; Havana. Havana: Ministry of Public Health (CU); 2009. Spanish.

  15. Montalvo MC, Delgado G, Díaz M, Rodríguez L. Prevalence of hepatitis B virus markers and risk factors associated in haemodialysis patients from Havana City; 2002-2003. Nefrologia. 2007;27(2):234–5.

  16. Ballester JM, Rivero RA, Villaescusa R, Merlín JC, Arce AA, Castillo D, et al. Hepatitis C virus antibodies and other markers of blood-transfusion–transmitted infection in multi-transfused Cuban patients. J Clin Virol. 2005 Dec;34 Suppl 2:S39–46.

  17. Santos EA, Yoshida CF, Rolla VC, Mendes JM, Vieira IF, Arabe J, et al. Frequent occult hepatitis B virus infection in patients infected with human immunodefi ciency virus type 1. Eur J Clin Microbiol Infect Dis. 2003 Feb;22(2):92–8.

  18. Diop-Ndiaye H, Touré-Kane C, Etard JF, Lô G, Diaw P, Ngom-Gueye NF, et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol. 2008 Aug;80(8):1332–6.

  19. Quarleri J, Moretti F, Bouzas MB, Laufer N, Carrillo MG, Giuliano SF, et al. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses. 2007 Apr;23(4):525–31.

  20. Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, Maskew M, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis. 2009 Jul;13(4): 488–92.

  21. Palacios R, Mata R, Hidalgo A, Muñoz L, Viciana I, Del Arco A, et al. Very low prevalence and no clinical signifi cance of occult hepatitis B in a cohort of HIV-infected patients with isolated anti- HBc seropositivity: the BHOI study. HIV Clin Trials. 2008 Sep–Oct;9(5):337–40.

  22. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol. 2007 Oct;79(10):1464–71.

  23. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006 Jun 12;20(9):1253–60.

  24. Sucupira MV, Mello FC, Santos EA, Niel C, Rolla VC, Arabe J, et al. Patterns of hepatitis B virus infection in Brazilian human immunodefi ciency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz. 2006 Sep;101(6):655–60.

  25. Bello, Marité (Institute of Tropical Medicine, Havana, Cuba). Conversation with: Licourt Tania, Delgado Graciela, Suárez Angel, Lefrán María Elena, Fonte Maira (Immunoesssay Center, Havana, Cuba). 2009 April 24.

  26. Laguno M, Larrousse M, Blanco JL, León A, Milinkovic A, Martínez-Rebozler M, et al. Prevalence and clinical relevance of occult hepatitis B in the fi brosis progression and antiviral response to INF therapy in HIV-HCV–coinfected patients. AIDS Res Hum Retroviruses. 2008 Apr;24(4):547–53.

  27. Arababadi MK, Hassanshahi G, Yousefi H, Zarandi ER, Moradi M, Mahmoodi M. No detected hepatitis B virus-DNA in thalassemic patients infected by hepatitis C virus in Kerman province of Iran. Pak J Biol Sci. 2008 Jul 1;11(13):1738–41.

  28. Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion. 2007 Jan;47(1):74–9.

  29. Pérez-Rodríguez MT, Sopeña B, Crespo M, Rivera A, González del Blanco T, Ocampo A, et al. Clinical signifi cance of “anti-HBc” in human immunodefi ciency virus-positive patients. World J Gastroenterol. 2009 Mar 14;15(10):1237–41.

  30. Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, et al. Isolated antibody to hepatitis B core antigen in human immunodefi ciency virus type-1–infected individuals. Clin Infect Dis. 2003 Jun 15;36(12):1602–5.

  31. Ministry of Public Health (CU). Informe Nacional sobre los progresos realizados en la aplicación del UNGASS, Cuba, 2008 [Internet]. Geneva: UNAIDS; 2010 Mar [cited 2010 Jun 20]. 39 p. Available from: http://data.unaids.org/pub/Report/ 2008/cuba_2008_country_progress_report_ sp_es.pdf. Spanish.

  32. Montalvo Villalba MC. Perfi l seroepdemiológico del virus de la hepatitis B en pacientes hemodializados de Ciudad Habana [master’s thesis]. Havana: Pedro Kourí Tropical Medicine Institute. (CU); 2004. 67 p. Spanish.

  33. Neau D, Winnock M, Galpérine T, Jouvencel AC, Castéra L, Legrand E, et al. Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med. 2004 May;5(3):171–3.

  34. Rodríguez-Torres M, González-García J, Bräu N, Solá R, Moreno S, Rockstroh J, et al. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodefi - ciency virus (HIV) co-infection: clinically relevant or a diagnostic problem? J Med Virol. 2007 Jun;79(6):694–700.

  35. Ramia S, Mokhbat J, Ramlawi F, El-Zaatari M. Occult hepatitis B virus infection in HIV-infected Lebanese patients with isolated antibodies to hepatitis B core antigen. Int J STD AIDS. 2008 Mar;19(3):197–9.

  36. French AL, Operskalski E, Peters M, Strickler HD, Tien PC, Sharp GB, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis. 2007 May 15;195(10):1437–42.

  37. Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis vaccine injections augments anti- HBs response rate in HIV- infected patients. Effect on HIV-1 viral load. Vaccine. 2000 Jan 18;18(13):1161–5.

  38. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients, Italy. Vaccine. 2009 Jan 1;27(1):17–22.

  39. Kupski C, Träsel FR, Mazzoleni F, Winckler MA, Bender AL, Machado DC, et al. Serologic and molecular profi le of anti–HBc-positive blood bank donors in an area of low endemicity for HBV. Dig Dis Sci. 2008 May;53(5):1370–4.

  40. Piroth L, Lafon ME, Binquet C, Bertillon P, Gervais A, Lootvoet E, et al. Occult hepatitis B in HIV-HCV coinfected patients. Scand J Infect Dis. 2008;40(10):835–9.

  41. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defi c Syndr. 2004 Jul 1;36(3):869–75.

  42. Tsui JI, French AL, Seaberg EC, Augenbraun M, Nowicki M, Peters M, et al. Prevalence and longterm effects of occult hepatitis B virus infection in HIV-infected women. Clin Infect Dis. 2007 Sep 15;45(6):736–40.

  43. Lo Re V 3rd, Wertheimer B, Localio AR, Kostman JR, Dockter J, Linnen JM, et al. Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol. 2008 Sep;43(1):32–6.

  44. Pérez J, Pérez CD, González I, Díaz-Jidy M, Millán JC, Orta M. Pautas Cubanas para el tratamiento antirretroviral en los pacientes con VIH/ SIDA. Havana: Ministry of Public Health (CU); 2004. 64 p. Spanish.

  45. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol. 2004 Feb;11(1):18–25.

  46. Torres-Baranda R, Bastidas-Ramírez BE, Maldonado-González M, Sánchez-Orozco LV, Vázquez-Vals E, Rodríguez-Noriega E, et al. Occult hepatitis B in Mexican patients with HIV, an analysis using nested polymerase chain reaction. Ann Hepatol. 2006 Jan–Mar;5(1):34–40.




2020     |     www.medigraphic.com